{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:12:56Z","timestamp":1791274376106,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"DOI":"10.1186\/s40842-025-00251-7","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T23:01:34Z","timestamp":1765321294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9139-7159","authenticated-orcid":false,"given":"Dario","family":"Tuccinardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Zilich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ponzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Musacchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Manicardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pontremoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fioretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Muscar\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziano","family":"Di Cianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Candido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-8286","authenticated-orcid":false,"given":"Salvatore A.","family":"De Cosmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4565-3131","authenticated-orcid":false,"given":"Giuseppina","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of AMD Annals study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"12","key":"251_CR1","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","volume":"65","author":"E Marilly","year":"2022","unstructured":"Marilly E, Cottin J, Cabrera N, et al. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia. 2022;65(12):2000\u201310.","journal-title":"Diabetologia"},{"issue":"1","key":"251_CR2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","volume":"21","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Jiang L, Wang J, et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol. 2022;21(1):232.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"251_CR3","first-page":"846","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee MMY, Sattar N, Pop-Busui R, et al. Cardiovascular and kidney outcomes and mortality with Long-Acting injectable and oral Glucagon-Like peptide 1 receptor agonists in individuals with type 2 diabetes: A systematic review and Meta-analysis of randomized trials. Diabetes Care. 2025;48(5):846\u201359.","journal-title":"Diabetes Care"},{"issue":"10","key":"251_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10166","key":"251_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"1","key":"251_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000503919","volume":"10","author":"KB Lo","year":"2020","unstructured":"Lo KB, Gul F, Ram P, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: A systematic review and Meta-Analysis. Cardiorenal Med. 2020;10(1):1\u201310.","journal-title":"Cardiorenal Med"},{"issue":"Supplement1","key":"251_CR7","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice C","year":"2025","unstructured":"American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2025. Diabetes Care. 2025;48(Supplement1):S181\u2013206.","journal-title":"Diabetes Care"},{"issue":"1","key":"251_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12933-022-01713-3","volume":"21","author":"KL Funck","year":"2022","unstructured":"Funck KL, Bjerg L, Isaksen AA, Sandbaek A, Grove EL. Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study. Cardiovasc Diabetol. 2022;21(1):279.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"251_CR9","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2666-7568(23)00164-2","volume":"4","author":"ME Malik","year":"2023","unstructured":"Malik ME, Butt JH, Strange JE, et al. Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in denmark: a cross-sectional, nationwide study. Lancet Healthy Longev. 2023;4(10):e552\u201360.","journal-title":"Lancet Healthy Longev"},{"issue":"12","key":"251_CR10","doi-asserted-by":"publisher","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Essien UR, et al. Racial, Ethnic, and socioeconomic inequities in Glucagon-Like Peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum. 2021;2(12):e214182.","journal-title":"JAMA Health Forum"},{"key":"251_CR11","doi-asserted-by":"publisher","first-page":"100308","DOI":"10.1016\/j.lanepe.2022.100308","volume":"14","author":"AC Falkentoft","year":"2022","unstructured":"Falkentoft AC, Andersen J, Malik ME, et al. Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study. Lancet Reg Health Eur. 2022;14:100308.","journal-title":"Lancet Reg Health Eur"},{"key":"251_CR12","doi-asserted-by":"publisher","first-page":"1606198","DOI":"10.3389\/fcvm.2025.1606198","volume":"12","author":"S Agarwal","year":"2025","unstructured":"Agarwal S, Basit MA, Bowen ME, et al. Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes. Front Cardiovasc Med. 2025;12:1606198.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"251_CR13","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.2337\/dc20-2926","volume":"44","author":"H Shin","year":"2021","unstructured":"Shin H, Schneeweiss S, Glynn RJ, Patorno E. Trends in First-Line Glucose-Lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA. Diabetes Care. 2021;44(8):1774\u201382.","journal-title":"Diabetes Care"},{"issue":"11","key":"251_CR14","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1111\/dom.15912","volume":"26","author":"A Potteg\u00e5rd","year":"2024","unstructured":"Potteg\u00e5rd A, Andersen JH, S\u00f8ndergaard J, et al. Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies. Diabetes Obes Metab. 2024;26(11):4996\u20135004.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"251_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"251_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12933-024-02500-y","volume":"23","author":"K Sawami","year":"2024","unstructured":"Sawami K, Tanaka A, Node K. Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives. Cardiovasc Diabetol. 2024;23(1):410.","journal-title":"Cardiovasc Diabetol"},{"issue":"17","key":"251_CR17","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Petrie MC, Borlaug BA, et al. Inflammation in Obesity-Related hfpef: the STEP-HFpEF program. J Am Coll Cardiol. 2024;84(17):1646\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"251_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000480525","volume":"10","author":"DR Leitner","year":"2017","unstructured":"Leitner DR, Fruhbeck G, Yumuk V, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment Strategies - EASO can lead the way. Obes Facts. 2017;10(5):483\u201392.","journal-title":"Obes Facts"},{"key":"251_CR19","doi-asserted-by":"crossref","unstructured":"Pierson E, Shanmugam D, Movva R, et al. Using large language models to promote health equity. NEJM AI. 2025;2(2).","DOI":"10.1056\/AIp2400889"},{"issue":"4","key":"251_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2337\/dc21-1722","volume":"45","author":"H Tang","year":"2022","unstructured":"Tang H, Kimmel SE, Smith SM, et al. Comparable cardiorenal benefits of SGLT2 inhibitors and GLP-1RAs in Asian and white populations: an updated Meta-analysis of results from randomized outcome trials. Diabetes Care. 2022;45(4):1007\u201312.","journal-title":"Diabetes Care"},{"issue":"5","key":"251_CR21","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"251_CR22","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00592-023-02107-x","volume":"60","author":"E Mannucci","year":"2023","unstructured":"Mannucci E, Candido R, Monache LD, et al. 2023 update on Italian guidelines for the treatment of type 2 diabetes. Acta Diabetol. 2023;60(8):1119\u201351.","journal-title":"Acta Diabetol"},{"key":"251_CR23","doi-asserted-by":"publisher","first-page":"100666","DOI":"10.1016\/j.lanepe.2023.100666","volume":"31","author":"A Ceriello","year":"2023","unstructured":"Ceriello A, Lucisano G, Prattichizzo F, et al. The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes. Lancet Reg Health Eur. 2023;31:100666.","journal-title":"Lancet Reg Health Eur"},{"issue":"5","key":"251_CR24","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/ndt\/gfac280","volume":"38","author":"P McEwan","year":"2023","unstructured":"McEwan P, Boyce R, Sanchez JJG, et al. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrol Dial Transpl. 2023;38(5):1260\u201370.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"251_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-Glucose Cotransporter-2 inhibitors and the risk for severe urinary tract infections: A Population-Based cohort study. Ann Intern Med. 2019;171(4):248\u201356.","journal-title":"Ann Intern Med"},{"issue":"1","key":"251_CR26","doi-asserted-by":"publisher","first-page":"18290","DOI":"10.1038\/s41598-024-69016-z","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, Su X, Hao Y, investigators CMS. Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese Doctors. Sci Rep. 2024;14(1):18290.","journal-title":"Sci Rep"},{"key":"251_CR27","doi-asserted-by":"publisher","first-page":"108737","DOI":"10.1016\/j.diabres.2021.108737","volume":"174","author":"T Karagiannis","year":"2021","unstructured":"Karagiannis T, Tsapas A, Athanasiadou E, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;174:108737.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"251_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Heerspink HJL, Vart P, et al. Estimated lifetime Cardiovascular, Kidney, and mortality benefits of combination treatment with SGLT2 Inhibitors, GLP-1 receptor Agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024;149(6):450\u201362.","journal-title":"Circulation"},{"issue":"5","key":"251_CR29","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","volume":"15","author":"S Seidu","year":"2024","unstructured":"Seidu S, Alabraba V, Davies S, et al. SGLT2 Inhibitors - The new standard of care for Cardiovascular, renal and metabolic protection in type 2 diabetes: A narrative review. Diabetes Ther. 2024;15(5):1099\u2013124.","journal-title":"Diabetes Ther"},{"key":"251_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pcad.2023.05.003","volume":"78","author":"EK Aryee","year":"2023","unstructured":"Aryee EK, Ozkan B, Ndumele CE. Heart failure and obesity: the latest pandemic. Prog Cardiovasc Dis. 2023;78:43\u20138.","journal-title":"Prog Cardiovasc Dis"},{"issue":"16","key":"251_CR31","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"11","key":"251_CR32","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor Dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954\u201360.","journal-title":"Nat Med"},{"issue":"3","key":"251_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-8587(24)00304-8","volume":"13","author":"MJ Davies","year":"2025","unstructured":"Davies MJ, van der Meer P, Verma S, et al. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2025;13(3):196\u2013209.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"251_CR34","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00251-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-025-00251-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00251-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T23:01:35Z","timestamp":1765321295000},"score":1,"resource":{"primary":{"URL":"https:\/\/clindiabetesendo.biomedcentral.com\/articles\/10.1186\/s40842-025-00251-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["251"],"URL":"https:\/\/doi.org\/10.1186\/s40842-025-00251-7","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and national guidelines on using anonymised healthcare data. Under national regulations for retrospective studies involving de-identified electronic health records, ethical approval and patient consent were waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}